NASDAQ: CGEM

Cullinan Therapeutics, Inc.

Healthcare | Medical - Pharmaceuticals

No licensed closing price on file for CGEM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2021)$-1.52

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a pharmaceutical company. Figures from SEC EDGAR; updated 2026-10-19 23:23 UTC.

What Cullinan Therapeutics, Inc. does

The company is a biopharmaceutical firm developing therapies for autoimmune diseases and cancer, with core expertise in T cell engagers. In immunology, it is testing CLN-978, a bispecific T cell engager, in patients with systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's disease through the Phase 1 OUTRACE program, while also advancing velinotamig through a licensed partner.

Summarized from Cullinan Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-06-16
EPS (FY2021)	$-1.52

Charts

Charts are in the appInteractive charts for CGEM are available in Oxford Ledge.
Open CGEM in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-10

2026-09-10Chief Scientific OfficerOption exercise4,000$17.2K
2026-09-10Chief Scientific OfficerSale-8,000$172.6K
2026-09-10Chief Scientific OfficerStock Option (Right to Buy)Option exercise-4,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

MPM BIOIMPACT LLC9,731,341$177.21M+27.2%
Lynx1 Capital Management LP8,963,500$163.23M0.0%
BVF INC/IL5,750,683$104.72M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-05-15Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-04-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Questions this page answers

What does Cullinan Therapeutics, Inc. do?

The company is a biopharmaceutical firm developing therapies for autoimmune diseases and cancer, with core expertise in T cell engagers.

When did CGEM last file with the SEC?

Cullinan Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-16. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:23 UTC. This page is also available as JSON at /api/data?ticker=CGEM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CGEM and 5,000+ tickers.

Create a free account — keep CGEM

For your agent

GET /api/data?ticker=CGEM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt